Physician profile
John Nipper
NPI 1083690465
$3,888.79
in general payments reported to CMS, 2019-2025
32 companies · $562 in 2025
The $562 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $827 · 2020: $407 · 2021: $702 · 2022: $591 · 2023: $403 · 2024: $397 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,361.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $667.71 | 2019-2023 | Krystexxa |
| Amgen INC. | $486.26 | 2019-2025 | Krystexxa, Tavneos, Uplizna |
| Bard Peripheral Vascular, INC. | $416.77 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $309.48 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $286.29 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $196.29 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $147.11 | 2021-2024 | |
| Mallinckrodt Hospital Products INC. | $142.73 | 2023-2025 | Acthar |
| Silk Road Medical, INC. | $123.76 | 2021 | |
| Janssen Pharmaceuticals, INC | $119.17 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $105.21 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $95.60 | 2021-2024 | Lupkynis |
| Nxstage Medical, INC. | $85.49 | 2023 | Liberty Select Cycler, Nxstage System One |
| Scpharmaceuticals INC. | $80.53 | 2025 | |
| Akebia Therapeutics INC | $75.85 | 2020-2024 | Auryxia, Vafseo |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $71.63 | 2019-2022 | |
| Calliditas Therapeutics US INC. | $58.92 | 2024-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $50.22 | 2019-2024 | |
| Glaxosmithkline, LLC. | $46.12 | 2021-2023 | Jesduvroq |
| Medtronic, INC. | $43.17 | 2021 | |
| Travere Therapeutics, INC. | $39.05 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $38.53 | 2021-2025 | Ultomiris |
| Biom'Up France Sas | $26.74 | 2020 | |
| Opko Pharmaceuticals, LLC | $24.89 | 2019 | |
| Mozarc Medical US LLC | $23.26 | 2025 | Palindrome |
| Cook Medical LLC | $20.37 | 2022 | |
| Genzyme Corporation | $20.27 | 2019 | |
| Abbott Laboratories | $20.20 | 2019 | |
| Mallinckrodt Enterprises LLC | $19.84 | 2019 | |
| Siemens Medical Solutions USA, INC. | $17.92 | 2020 | |
| Shire North American Group INC | $14.85 | 2019 | |
| Novo Nordisk INC | $14.56 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Nipper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.